There is increasing evidence that an ongoing systemic inflammatory response is associated with poor outcome in patients with advanced cancer.
Dr McMillan and colleagues from the United Kingdom examined whether an inflammation-based prognostic score was associated with survival.
The research team assessed the Glasgow Prognostic score in 258 patients with inoperable gastro-esophageal cancer.
The patients also had measurements of albumin and C-reactive protein concentrations, at the time of diagnosis.
Clinical information was obtained from a gastro-esophageal cancer database and analysis of the case notes.
Patients with both an elevated C-reactive protein and hypoalbuminaemia were allocated a score of 2.
|The 12-month cancer-specific survival in stage I/II disease was 67% for a score of 0|
|British Journal of Cancer|
Patients in whom only 1 of these biochemical abnormalities was present were allocated a score of 1.
The team gave patients with a normal C-reactive protein and albumin a score of 0.
On multivariate survival analysis, age, stage, the score, and treatment were significant independent predictors of cancer survival.
The team found that a 12-month cancer-specific survival in stage I/II disease with active treatment was 67% and 60% for a score of 0 and 1, respectively.
For stage III/IV disease, 12 months cancer-specific survival was 57%, 25% and 12% for a score of 0, 1 and 2, respectively.
Dr McMillan's team concludes, “The score predicted cancer-specific survival, independent of stage and treatment received, in patients with inoperable gastro-esophageal cancer.”
“Moreover, the score may be used in combination with conventional staging techniques to improve the prediction of survival in patients with inoperable gastro-esophageal cancer.”